Should Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) investors track the following data?
Now, according to many market players, hedge funds are assumed to be bloated, outdated investment tools of a period lost to current times. Although there are In excess of 8,000 hedge funds with their doors open in present day, this site focuses on the elite of this club, close to 525 funds. It is widely held that this group oversees the lion’s share of the hedge fund industry’s total assets, and by paying attention to their best stock picks, we’ve spotted a number of investment strategies that have historically outstripped Mr. Market. Our small-cap hedge fund strategy beat the S&P 500 index by 18 percentage points per year for a decade in our back tests, and since we’ve started sharing our picks with our subscribers at the end of August 2012, we have trumped the S&P 500 index by 33 percentage points in 11 months (see all of our picks from August).
Just as necessary, positive insider trading activity is a second way to look at the world of equities. Obviously, there are lots of stimuli for a corporate insider to sell shares of his or her company, but only one, very simple reason why they would initiate a purchase. Plenty of empirical studies have demonstrated the impressive potential of this tactic if you know what to do (learn more here).
Thus, it’s important to discuss the recent info for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
Hedge fund activity in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Heading into Q3, a total of 21 of the hedge funds we track were bullish in this stock, a change of 11% from the first quarter. With hedgies’ sentiment swirling, there exists a select group of key hedge fund managers who were boosting their holdings considerably.
According to our 13F database, Visium Asset Management, managed by Jacob Gottlieb, holds the biggest position in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Visium Asset Management has a $76.1 million position in the stock, comprising 1.8% of its 13F portfolio. The second largest stake is held by Matt Sirovich and Jeremy Mindich of Scopia Capital, with a $55.8 million position; 1.6% of its 13F portfolio is allocated to the stock. Remaining hedgies that are bullish include William Leland Edwards’s Palo Alto Investors, Rob Citrone’s Discovery Capital Management and Ken Griffin’s Citadel Investment Group.
Now, specific money managers have jumped into Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) headfirst. Visium Asset Management, managed by Jacob Gottlieb, created the most outsized position in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Visium Asset Management had 76.1 million invested in the company at the end of the quarter. Matt Sirovich and Jeremy Mindich’s Scopia Capital also initiated a $55.8 million position during the quarter. The other funds with new positions in the stock are William Leland Edwards’s Palo Alto Investors, Rob Citrone’s Discovery Capital Management, and Ken Griffin’s Citadel Investment Group.
Insider trading activity in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Bullish insider trading is most useful when the company in question has experienced transactions within the past six months. Over the latest six-month time period, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has seen zero unique insiders purchasing, and zero insider sales (see the details of insider trades here).
We’ll also review the relationship between both of these indicators in other stocks similar to Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). These stocks are Akorn, Inc. (NASDAQ:AKRX), Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR), Hi-Tech Pharmacal Co. (NASDAQ:HITK), Sagent Pharmaceuticals Inc (NASDAQ:SGNT), and Ligand Pharmaceuticals Inc. (NASDAQ:LGND). This group of stocks are in the drugs – generic industry and their market caps match MNTA’s market cap.
